4 October 20233 minute read

DLA Piper Life Sciences Summit

Wednesday, October 4, 2023

9:00 am - 5:00 pm ET
Reception to follow

DLA Piper’s inaugural Life Sciences Summit will take place on Wednesday, October 4 in New York City. The summit will bring together pharmaceutical, biotechnology, and medical device companies from around the world and at all stages of the life cycle to discuss emerging trends and challenges facing the industry.

DLA Piper’s life sciences team will lead discussions with our clients on diverse topics of interest to high-level lawyers involved in a wide array of issues facing the industry, including:

  • Political and legal challenges facing the life sciences industry
  • The future of drug pricing in the wake of the Inflation Reduction Act
  • Protecting your intellectual property around the world in an ever-changing patent landscape, including the Unified Patent Court and beyond
  • The current state of financing and M&A for life sciences companies
  • Challenges life sciences companies face when expanding and doing business around the world
  • The legal challenges raised by the rapid expansion of artificial intelligence
  • FDA regulation of new medical technologies


etc.venues 360 Madison
360 Madison Avenue
5th Floor
New York, NY 10017

For more information
Please contact Shannon Tomassi with questions.

CLE Information
DLA Piper LLP (US) has been certified by the State Bar of California, Illinois MCLE Board, the Board on Continuing Legal Education of the Supreme Court of New Jersey, and the New York State Continuing Legal Education Board as an Accredited Provider. The following CLE credit is being sought:

  • California: 2.25 Credit (2.25 General, 0.0 Ethics)
  • Illinois: 2.25 Credit (2.25 General, 0.0 Professional Responsibility)
  • New Jersey: 2.7 Credits (2.7 General, 0.0 Ethics)
  • New York: 2.5 Transitional & Non-Transitional Credit (2.5 Professional Practice, 0.0 Ethics)

CLE credit will be applied for in other states where DLA Piper has an office with the exception of Minnesota, North Carolina, Pennsylvania, and Puerto Rico.


Anne Baker
Director of Legal Affairs, Regulatory, Quality & Compliance
  Subin Baral
Global Deals Leader, Life Sciences
Ernst & Young
John A. Bardi
SVP, Market Access, Policy and Government Affairs
Intra-Cellular Therapies
             Karen Day
Senior Counsel
Michael Haughney
Director, Global Compliance Monitoring and Analytics
Bristol Myers Squibb
  Chris Jewell
SVP and General Counsel
Taiho Oncology
Monaya Krause
Chief Global Regulatory Counsel
GE HealthCare
  Brian O'Callaghan
CEO and Board Member
Deep Genomics
Kenneth Peist
VP, Intellectual Property
Dermavant Sciences
  Angela Riemer
SVP, Global Policy & Public Affairs
Philip Ross
Global Chairman
J.P. Morgan Healthcare Investment Banking
  Aviva Wein
Assistant General Counsel, Products Liability
Johnson & Johnson
Dr. Chen-Sen "Samson" Wu
General Counsel, Patient Care Solutions
GE HealthCare

DLA Piper Speakers


9:00 am - Registration and breakfast

10:00 am - Introductory remarks
Loren H. Brown, US Vice Chairman and Chair of US Disputes practice

10:05 am - Political and legal challenges facing the life sciences industry
Former Senator Richard Burr and former Congressman Jim Greenwood

10:50 am - The future of drug pricing in the wake of the Inflation Reduction Act
Kirsten Axelsen, John Bardi (Intra-Cellular Therapies), Rachel Portman, Angela Riemer (Pfizer)

11:35 am - Protecting your IP around the world in the era of an ever-changing patent landscape: The UPC and beyond
Gualtiero Dragotti, Nicole Endejann, Chris Jewell (Taiho Oncology), Amy Lydon (Medtronic), Kenneth Peist (Dermavant Sciences)

12:20 pm - Lunch and networking

1:20 pm - The market for innovation: Current state of life sciences financings and M&A
Andy Gilbert, Philip Ross (J.P. Morgan Healthcare Investment Banking)

2:20 pm - Strategies for Companies Expanding Globally
Jeff Baglio, Subin Baral (Ernst & Young), Maruti Narayan, Brian O'Callaghan (Deep Genomics), Victoria Rhodes

3:05 pm - Coffee and cookies break

3:25 pm - The rise of big data: Legal challenges raised by artificial intelligence and other data science trends
Michael Haughney (Bristol Myers Squibb), Danny Tobey, Aviva Wein (Johnson & Johnson), Dr. Chen-Sen "Samson" Wu (GE HealthCare)

4:10 pm - FDA regulation of new medical technologies
Anne Baker (Dexcom), Karen Day (Pfizer), Perham Gorji, Monaya Krause (GE HealthCare), Geoffrey Levitt, Keo Shaw

4:55 pm - Closing remarks
Loren H. Brown, US Vice Chairman and Chair of US Disputes practice

5:00 pm - Cocktail reception